A Phase IIIb, Randomized, Multicenter, Open-Label Study of Atezolizumab Plus Bevacizumab Versus Transarterial Chemoembolization (TACE) in Intermediate-Stage Hepatocellular Carcinoma

PI: Dr. Vincenzo Mazzaferro 

The primary purpose of this Phase IIIb study is to evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared to TACE in patients with intermediate-stage HCC  

• Arm A (experimental arm):  
  Atezolizumab 1200 mg intravenous (IV) infusions Q3W (given in 3-week cycles); 
  Bevacizumab 15 mg/kg IV Q3W (given in 3-week cycles)  
• Arm B (standard arm):  
  Transarterial chemoembolization (using conventional TACE [cTACE] or drug-eluting bead-based TACE [DEB-TACE];  

Eligibility of potential study participants will be assessed during a 28-day screening period. The first treatment should be performed as soon as possible, but no later than 10 working days after randomization. Eligible patients will be enrolled and randomized to systemic treatment with atezolizumab + bevacizumab or locoregional treatment with TACE.  

Randomization will be in a 1:1 ratio